Understand the source comparison
Best Peptides for Women 55+ Postmenopause: Clinical Comparison
Before selecting a peptide protocol, compare mechanisms, administration logistics, and clinical endpoints relevant to postmenopausal physiology. BPC-157 VEGF upregulation, collagen synthesis Daily subcutaneous (250–500mcg) 18% increase in trabecular bone volum
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide protocol, compare mechanisms, administration logistics, and clinical endpoints relevant to postmenopausal physiology.
- BPC-157
- VEGF upregulation, collagen synthesis
- Daily subcutaneous (250–500mcg)
- 18% increase in trabecular bone volume (animal), faster soft tissue repair (observational)
- Best for joint pain and tissue repair. No hormonal interference
- CJC-1295 + Ipamorelin
- GHRH/ghrelin receptor activation, pulsatile GH
- 3× weekly subcutaneous (100mcg each)
- 2.8kg lean mass gain, 11% visceral fat reduction over 24 weeks
- Gold standard for sarcopenia and body recomposition without glucose impact
- TB-500
- Actin polymerization, fibroblast activation
- 2× weekly subcutaneous (2–5mg loading, 1–2mg maintenance)
- 2.4-fold increase in collagen mRNA (in vitro)
- Strongest collagen signal. Critical for tendon and skin integrity
- MOTS-c
- AMPK activation, mitochondrial biogenesis
- 3× weekly subcutaneous (10mg)
- 34% glucose tolerance improvement (animal menopause model)
- Best metabolic peptide for insulin resistance. Pairs with AOD-9604
- Tesamorelin
- GHRH analog, visceral fat reduction
- Daily subcutaneous (2mg)
- 15–20% visceral fat reduction, improved lipid panels (FDA trial data)
- FDA-approved, strongest visceral fat evidence. Shorter half-life than CJC-1295